The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre‐eclampsia. Outcome for children at 18 months
Objective To assess the long‐term effects of in utero exposure to magnesium sulphate for children whose mothers had pre‐eclampsia. Design Assessment at 18 months of age for children whose mothers were recruited to the Magpie Trial (recruitment 1998–2001 ISRCTN 86938761), which compared magnesium s...
Gespeichert in:
| Veröffentlicht in: | BJOG : an international journal of obstetrics and gynaecology 2007-03, Vol.114 (3), p.289-299 |
|---|---|
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 299 |
|---|---|
| container_issue | 3 |
| container_start_page | 289 |
| container_title | BJOG : an international journal of obstetrics and gynaecology |
| container_volume | 114 |
| description | Objective To assess the long‐term effects of in utero exposure to magnesium sulphate for children whose mothers had pre‐eclampsia.
Design Assessment at 18 months of age for children whose mothers were recruited to the Magpie Trial (recruitment 1998–2001 ISRCTN 86938761), which compared magnesium sulphate with placebo.
Setting Follow‐up of children born at 125 centres in 19 countries across five continents.
Population A total of 6922 children were born to women randomised before delivery at follow‐up centres. Of these, 2271 were not included for logistic reasons and 168 were excluded (101 at a centre where |
| doi_str_mv | 10.1111/j.1471-0528.2006.01165.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2063969</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69039742</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5295-6769217c729ba7faf250860389d8de8e9ac5d56d05e20a71c9740f656194491f3</originalsourceid><addsrcrecordid>eNqNkc1u1DAUhSMEoqXwCshCgt0E_0ycGAkkqPhV0WyGtXXHuZl45MTBTmi7Y8OeZ-RJcGZGLbDCG1_5fj4-1yfLCKM5S-v5LmfLki1owaucUypzypgs8qs72elN4-6-pgsqeHWSPYhxRymTnIr72QkrmZScs9Psx7pF8hm2g0WyDhbcCwIkQF_7zkasyTifEeO7AYLtt6SDbY_RTh2JkxtaGJFc2rElgwODG08aH8gQ8Nf3n2gcdEO0kJPVNCYF3DdNa10dsCcwElaRzvdjGx9m9xpwER8d97Psy7u36_MPi4vV-4_nry8WpuCqWMhSKs5KU3K1gbKBhhe0klRUqq5qrFCBKepC1rRATqFkRpVL2shCMrVcKtaIs-zVQXeYNh3WBvsxgNNDsB2Ea-3B6r87vW311n_TnEqhpEoCz44CwX-dMI46fZNB56BHP0UtFRXpUZ7AJ_-AOz-FPg2nOU-GqChpgqoDZIKPMWBz44RRPQetd3rOU8956jlovQ9aX6Wrj_-c5PbiMdkEPD0CEA24JmVqbLzlqkJUQsweXh64S-vw-r8N6DefVnMlfgM9IcWT</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>225610370</pqid></control><display><type>article</type><title>The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre‐eclampsia. Outcome for children at 18 months</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creatorcontrib>Magpie Trial Follow-Up Study Collaborative Group ; Magpie Trial Follow‐Up Study Collaborative Group</creatorcontrib><description>Objective To assess the long‐term effects of in utero exposure to magnesium sulphate for children whose mothers had pre‐eclampsia.
Design Assessment at 18 months of age for children whose mothers were recruited to the Magpie Trial (recruitment 1998–2001 ISRCTN 86938761), which compared magnesium sulphate with placebo.
Setting Follow‐up of children born at 125 centres in 19 countries across five continents.
Population A total of 6922 children were born to women randomised before delivery at follow‐up centres. Of these, 2271 were not included for logistic reasons and 168 were excluded (101 at a centre where <20% were contacted, 40 whose death or disability was due to a problem at conception or embryogenesis and 27 whose parent/s opted out). Therefore, 4483 children were included in follow‐up, of whom 3283 (73%) were contacted.
Methods Assessment by questionnaire, with interview and neurodevelopmental testing of selected children.
Main outcome measures Death or neurosensory disability at age of 18 months.
Results Of those allocated magnesium sulphate, 245/1635 (15.0%) were dead or had neurosensory disability at 18 months compared with 233/1648 (14.1%) allocated placebo (relative risk [RR] 1.06, 95% CI 0.90–1.25), and of survivors, 19/1409 (1.3%) had neurosensory disability at 18 months compared with 27/1442 (1.9%) (RR 0.72, 95% CI 0.40–1.29). There were no substantial differences in causes of death or in the risk of individual impairments or disabilities.
Conclusions The lower risk of eclampsia following prophylaxis with magnesium sulphate was not associated with a clear difference in the risk of death or disability for children at 18 months.</description><identifier>ISSN: 1470-0328</identifier><identifier>EISSN: 1471-0528</identifier><identifier>DOI: 10.1111/j.1471-0528.2006.01165.x</identifier><identifier>PMID: 17166221</identifier><identifier>CODEN: BIOGFQ</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Anticonvulsants - adverse effects ; Biological and medical sciences ; Children & youth ; Clinical outcomes ; Clinical trials ; Dietary supplements ; Disability Evaluation ; Disabled Children ; Diseases of mother, fetus and pregnancy ; Female ; Gynecology. Andrology. Obstetrics ; Humans ; Hypertension ; Infant ; Longterm follow‐up ; Magnesium ; Magnesium Sulfate - adverse effects ; magnesium sulphate ; Maternal Medicine ; Medical sciences ; Nervous System Diseases - embryology ; Nervous System Diseases - mortality ; Obstetrics ; Pre-Eclampsia - drug therapy ; Pregnancy ; Pregnancy Outcome ; Pregnancy. Fetus. Placenta ; Prenatal Exposure Delayed Effects - chemically induced ; Prenatal Exposure Delayed Effects - mortality ; pre‐eclampsia ; randomised trial ; Sensation Disorders - embryology ; Sensation Disorders - mortality</subject><ispartof>BJOG : an international journal of obstetrics and gynaecology, 2007-03, Vol.114 (3), p.289-299</ispartof><rights>2006 The Authors Journal compilation</rights><rights>2007 INIST-CNRS</rights><rights>2006 The Authors Journal compilation © RCOG 2006 BJOG An International Journal of Obstetrics and Gynaecology 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5295-6769217c729ba7faf250860389d8de8e9ac5d56d05e20a71c9740f656194491f3</citedby><cites>FETCH-LOGICAL-c5295-6769217c729ba7faf250860389d8de8e9ac5d56d05e20a71c9740f656194491f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1471-0528.2006.01165.x$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1471-0528.2006.01165.x$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18538330$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17166221$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Magpie Trial Follow-Up Study Collaborative Group</creatorcontrib><creatorcontrib>Magpie Trial Follow‐Up Study Collaborative Group</creatorcontrib><title>The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre‐eclampsia. Outcome for children at 18 months</title><title>BJOG : an international journal of obstetrics and gynaecology</title><addtitle>BJOG</addtitle><description>Objective To assess the long‐term effects of in utero exposure to magnesium sulphate for children whose mothers had pre‐eclampsia.
Design Assessment at 18 months of age for children whose mothers were recruited to the Magpie Trial (recruitment 1998–2001 ISRCTN 86938761), which compared magnesium sulphate with placebo.
Setting Follow‐up of children born at 125 centres in 19 countries across five continents.
Population A total of 6922 children were born to women randomised before delivery at follow‐up centres. Of these, 2271 were not included for logistic reasons and 168 were excluded (101 at a centre where <20% were contacted, 40 whose death or disability was due to a problem at conception or embryogenesis and 27 whose parent/s opted out). Therefore, 4483 children were included in follow‐up, of whom 3283 (73%) were contacted.
Methods Assessment by questionnaire, with interview and neurodevelopmental testing of selected children.
Main outcome measures Death or neurosensory disability at age of 18 months.
Results Of those allocated magnesium sulphate, 245/1635 (15.0%) were dead or had neurosensory disability at 18 months compared with 233/1648 (14.1%) allocated placebo (relative risk [RR] 1.06, 95% CI 0.90–1.25), and of survivors, 19/1409 (1.3%) had neurosensory disability at 18 months compared with 27/1442 (1.9%) (RR 0.72, 95% CI 0.40–1.29). There were no substantial differences in causes of death or in the risk of individual impairments or disabilities.
Conclusions The lower risk of eclampsia following prophylaxis with magnesium sulphate was not associated with a clear difference in the risk of death or disability for children at 18 months.</description><subject>Anticonvulsants - adverse effects</subject><subject>Biological and medical sciences</subject><subject>Children & youth</subject><subject>Clinical outcomes</subject><subject>Clinical trials</subject><subject>Dietary supplements</subject><subject>Disability Evaluation</subject><subject>Disabled Children</subject><subject>Diseases of mother, fetus and pregnancy</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Infant</subject><subject>Longterm follow‐up</subject><subject>Magnesium</subject><subject>Magnesium Sulfate - adverse effects</subject><subject>magnesium sulphate</subject><subject>Maternal Medicine</subject><subject>Medical sciences</subject><subject>Nervous System Diseases - embryology</subject><subject>Nervous System Diseases - mortality</subject><subject>Obstetrics</subject><subject>Pre-Eclampsia - drug therapy</subject><subject>Pregnancy</subject><subject>Pregnancy Outcome</subject><subject>Pregnancy. Fetus. Placenta</subject><subject>Prenatal Exposure Delayed Effects - chemically induced</subject><subject>Prenatal Exposure Delayed Effects - mortality</subject><subject>pre‐eclampsia</subject><subject>randomised trial</subject><subject>Sensation Disorders - embryology</subject><subject>Sensation Disorders - mortality</subject><issn>1470-0328</issn><issn>1471-0528</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNqNkc1u1DAUhSMEoqXwCshCgt0E_0ycGAkkqPhV0WyGtXXHuZl45MTBTmi7Y8OeZ-RJcGZGLbDCG1_5fj4-1yfLCKM5S-v5LmfLki1owaucUypzypgs8qs72elN4-6-pgsqeHWSPYhxRymTnIr72QkrmZScs9Psx7pF8hm2g0WyDhbcCwIkQF_7zkasyTifEeO7AYLtt6SDbY_RTh2JkxtaGJFc2rElgwODG08aH8gQ8Nf3n2gcdEO0kJPVNCYF3DdNa10dsCcwElaRzvdjGx9m9xpwER8d97Psy7u36_MPi4vV-4_nry8WpuCqWMhSKs5KU3K1gbKBhhe0klRUqq5qrFCBKepC1rRATqFkRpVL2shCMrVcKtaIs-zVQXeYNh3WBvsxgNNDsB2Ea-3B6r87vW311n_TnEqhpEoCz44CwX-dMI46fZNB56BHP0UtFRXpUZ7AJ_-AOz-FPg2nOU-GqChpgqoDZIKPMWBz44RRPQetd3rOU8956jlovQ9aX6Wrj_-c5PbiMdkEPD0CEA24JmVqbLzlqkJUQsweXh64S-vw-r8N6DefVnMlfgM9IcWT</recordid><startdate>200703</startdate><enddate>200703</enddate><creator>Magpie Trial Follow-Up Study Collaborative Group</creator><creator>Magpie Trial Follow‐Up Study Collaborative Group</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>ASE</scope><scope>FPQ</scope><scope>K6X</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>200703</creationdate><title>The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre‐eclampsia. Outcome for children at 18 months</title></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5295-6769217c729ba7faf250860389d8de8e9ac5d56d05e20a71c9740f656194491f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Anticonvulsants - adverse effects</topic><topic>Biological and medical sciences</topic><topic>Children & youth</topic><topic>Clinical outcomes</topic><topic>Clinical trials</topic><topic>Dietary supplements</topic><topic>Disability Evaluation</topic><topic>Disabled Children</topic><topic>Diseases of mother, fetus and pregnancy</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Infant</topic><topic>Longterm follow‐up</topic><topic>Magnesium</topic><topic>Magnesium Sulfate - adverse effects</topic><topic>magnesium sulphate</topic><topic>Maternal Medicine</topic><topic>Medical sciences</topic><topic>Nervous System Diseases - embryology</topic><topic>Nervous System Diseases - mortality</topic><topic>Obstetrics</topic><topic>Pre-Eclampsia - drug therapy</topic><topic>Pregnancy</topic><topic>Pregnancy Outcome</topic><topic>Pregnancy. Fetus. Placenta</topic><topic>Prenatal Exposure Delayed Effects - chemically induced</topic><topic>Prenatal Exposure Delayed Effects - mortality</topic><topic>pre‐eclampsia</topic><topic>randomised trial</topic><topic>Sensation Disorders - embryology</topic><topic>Sensation Disorders - mortality</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Magpie Trial Follow-Up Study Collaborative Group</creatorcontrib><creatorcontrib>Magpie Trial Follow‐Up Study Collaborative Group</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>British Nursing Index</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BJOG : an international journal of obstetrics and gynaecology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><aucorp>Magpie Trial Follow-Up Study Collaborative Group</aucorp><aucorp>Magpie Trial Follow‐Up Study Collaborative Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre‐eclampsia. Outcome for children at 18 months</atitle><jtitle>BJOG : an international journal of obstetrics and gynaecology</jtitle><addtitle>BJOG</addtitle><date>2007-03</date><risdate>2007</risdate><volume>114</volume><issue>3</issue><spage>289</spage><epage>299</epage><pages>289-299</pages><issn>1470-0328</issn><eissn>1471-0528</eissn><coden>BIOGFQ</coden><abstract>Objective To assess the long‐term effects of in utero exposure to magnesium sulphate for children whose mothers had pre‐eclampsia.
Design Assessment at 18 months of age for children whose mothers were recruited to the Magpie Trial (recruitment 1998–2001 ISRCTN 86938761), which compared magnesium sulphate with placebo.
Setting Follow‐up of children born at 125 centres in 19 countries across five continents.
Population A total of 6922 children were born to women randomised before delivery at follow‐up centres. Of these, 2271 were not included for logistic reasons and 168 were excluded (101 at a centre where <20% were contacted, 40 whose death or disability was due to a problem at conception or embryogenesis and 27 whose parent/s opted out). Therefore, 4483 children were included in follow‐up, of whom 3283 (73%) were contacted.
Methods Assessment by questionnaire, with interview and neurodevelopmental testing of selected children.
Main outcome measures Death or neurosensory disability at age of 18 months.
Results Of those allocated magnesium sulphate, 245/1635 (15.0%) were dead or had neurosensory disability at 18 months compared with 233/1648 (14.1%) allocated placebo (relative risk [RR] 1.06, 95% CI 0.90–1.25), and of survivors, 19/1409 (1.3%) had neurosensory disability at 18 months compared with 27/1442 (1.9%) (RR 0.72, 95% CI 0.40–1.29). There were no substantial differences in causes of death or in the risk of individual impairments or disabilities.
Conclusions The lower risk of eclampsia following prophylaxis with magnesium sulphate was not associated with a clear difference in the risk of death or disability for children at 18 months.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>17166221</pmid><doi>10.1111/j.1471-0528.2006.01165.x</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1470-0328 |
| ispartof | BJOG : an international journal of obstetrics and gynaecology, 2007-03, Vol.114 (3), p.289-299 |
| issn | 1470-0328 1471-0528 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2063969 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Anticonvulsants - adverse effects Biological and medical sciences Children & youth Clinical outcomes Clinical trials Dietary supplements Disability Evaluation Disabled Children Diseases of mother, fetus and pregnancy Female Gynecology. Andrology. Obstetrics Humans Hypertension Infant Longterm follow‐up Magnesium Magnesium Sulfate - adverse effects magnesium sulphate Maternal Medicine Medical sciences Nervous System Diseases - embryology Nervous System Diseases - mortality Obstetrics Pre-Eclampsia - drug therapy Pregnancy Pregnancy Outcome Pregnancy. Fetus. Placenta Prenatal Exposure Delayed Effects - chemically induced Prenatal Exposure Delayed Effects - mortality pre‐eclampsia randomised trial Sensation Disorders - embryology Sensation Disorders - mortality |
| title | The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre‐eclampsia. Outcome for children at 18 months |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T12%3A40%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Magpie%20Trial:%20a%20randomised%20trial%20comparing%20magnesium%20sulphate%20with%20placebo%20for%20pre%E2%80%90eclampsia.%20Outcome%20for%20children%20at%2018%20months&rft.jtitle=BJOG%20:%20an%20international%20journal%20of%20obstetrics%20and%20gynaecology&rft.aucorp=Magpie%20Trial%20Follow-Up%20Study%20Collaborative%20Group&rft.date=2007-03&rft.volume=114&rft.issue=3&rft.spage=289&rft.epage=299&rft.pages=289-299&rft.issn=1470-0328&rft.eissn=1471-0528&rft.coden=BIOGFQ&rft_id=info:doi/10.1111/j.1471-0528.2006.01165.x&rft_dat=%3Cproquest_pubme%3E69039742%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=225610370&rft_id=info:pmid/17166221&rfr_iscdi=true |